anti-ILT4 monoclonal antibody CHS-1000

A Fc-modified humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the inhibitory immune checkpoint receptor immunoglobulin-like transcript 4 (LILRB2; ILT4; leukocyte immunoglobulin-like receptor subfamily B member 2; lymphocyte immunoglobulin-like receptor 2; LIR2; monocyte/macrophage immunoglobulin-like receptor 10; MIR-10; CD85d), with potential immunomodulating and antineoplastic activities. Upon administration, anti-ILT4 monoclonal antibody CHS-1000 targets and binds to LILRB2. This prevents the binding of LILRB2 ligands HLA-A and HLA-G to their receptor and prevents LILRB2-mediated signaling. This abrogates the immunosuppressive activities of LILRB2 in the tumor microenvironment (TME), promotes re-polarization of suppressive myeloid cells to a pro-inflammatory phenotype, enhances activation of dendritic cells (DCs) and T cells, and increases pro-inflammatory cytokine secretion leading to tumor cell death. ILILRB2, a transmembrane protein and inhibitory member of the immunoglobulin-like transcript (ILT) family of proteins, is expressed primarily by myeloid cells, including monocytes, macrophages, DCs and granulocytes, and in certain tumors. It plays a key role in tumor immune evasion.